Roles
- Genitourinary Site Disease Group Lead
- GU SDD Medical Oncology Lead
- Professor of Clinical Medicine
-
Biography
Dr. Marijo Bilusic, MD, PhD, is a board-certified medical oncologist who treats genitourinary tumors (adrenal, kidney, prostate, bladder, and testis). His current research interests focus on tumor immunology and the development of novel immunotherapy approaches for prostate cancer and other genitourinary tumors using therapeutic cancer vaccines, antibodies, immune modulators or immune checkpoint inhibitors, not only as monotherapies but in combination with other immune mediating modalities and other therapies as part of an immuno-oncology programmatic effort.
Dr. Bilusic received his M.D. degree from the University of Zagreb School of Medicine in Croatia and completed his Ph.D. training at the University of Split School of Medicine in Croatia. In addition, he completed a postdoctoral research fellowship in physiological genomics at the Medical College of Wisconsin's Human and Molecular Genetics Center in Milwaukee, WI. He successfully completed a clinical fellowship in medical oncology and hematology at the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI), in Bethesda, MD.
Dr. Bilusic served as an Assistant Professor Genitourinary medical oncology at the Fox Chase Cancer Center/Temple Health from 2012 – 2016 and then joined the NCI Genitourinary Malignancy Branch in 2016 as an Associate Research Physician (equivalent to Associate Professor). During his time at the NCI, he also served as Associate Program Director, NIH Hematology Oncology Fellowship Program from July 2016 – July 2018, and then as Program Director from July 2018 – July 2021. In 2017 Dr. Bilusic received the National Institutes of Health (NIH) Director's Award as a member of NIH Hematology Oncology Fellowship Team for extraordinary resourcefulness and initiative. His passion for teaching and mentoring has earned multiple awards at NIH and NCI.
In July 2021, Dr. Bilusic joined Sylvester Comprehensive Cancer Center / University of Miami Health System as GU Medical Oncology Team Lead. He is board-certified in medical oncology, hematology, and internal medicine. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Teaching Interests
Ars longa, vita brevis – Hippocrates.
As the previous director of the one of the most prestigious and one of the largest fellowship programs in the US, my view of the medical education guided my daily activities. Getting recruited back to the National Cancer Institute to lead the same program that I attended as a fellow several years prior was a great honor, privilege, and responsibility. My greatest professional sense of accomplishment comes from the mentoring 60+ fellows during 5 years of my service. A fellowship program director can influence the educational process in multiple ways: from curriculum development, fellows’ evaluation, mentoring and counseling, faculty development, to program development. Having a vision of the program’s goals, objectives and future is the main key for success. I like to use a healthy level of anxiety by asking questions and letting trainee struggle a bit for the answer. Then we discuss the sources used to provide the answer: clinical literature, clinical experience, or just ritual. Goals in teaching should not be limited only to the knowledge domain.
My tips for successful learning process are:
a) Set realistic expectations for trainees
b) Provide mentoring, tools, and develop skills
c) Offer guide toward intellectual and professional independence
d) Challenge the knowledge
e) Provide timely feedback
f) Build collegial relationship
g) Establish open door policy
h) Encourage peer learning
i) Develop individual learning plan
In summary, our job as faculty is to help future physicians in their professional development, and provide them tools, skills, and knowledge needed to advance the field of medicine. Hippocrates, the father of medicine and one of the greatest teachers, once wrote: while artists (doctors) die and are forgotten, art (medicine) lasts forever. -
Research Interests
Dr. Bilusic’s clinical research interests involve the translation of hypothesis-driven preclinical studies to genitourinary and phase 1 immunotherapy clinical trials in collaboration with investigators at the University of Miami, National Cancer Institute, other academic institutions, National Cancer Institute and industry. He focuses on understanding how the complex interplay between immune system and carcinogenesis affects development of genitourinary cancers and on identification of factors responsible for treatment resistance. His overall research goals focus on the design and development of novel therapeutic options such as cancer vaccines, immunocytokines, checkpoint inhibitors and targeted therapies using different strategies to modify the tumor microenvironment to make cancer cells susceptible to immune therapy.
Rational combination of approaches novel immune-mediating agents that can be used in combinations with standard-of-care therapies will hopefully address the underlying issues pertinent to a therapeutic immune response present within a tumor microenvironment and to explore changes in responders (especially exceptional responders) vs. non-responders to inform future studies. Building on his previous trial of bicalutamide with metformin in biochemically recurrent prostate cancer, Dr. Bilusic also studies novel agents in that space that can spare patients androgen deprivation therapy. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
How a Diabetes Drug May Echo the Benefits of Exercise in Prostate Cancer Care
Genomic Intelligence Improves Cancer Care
Sylvester Leads in Prostate Cancer Research and Treatment
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 14 clinical trials.
-
Part A: Investigate the safety and tolerability of KTX-2001 in participants with mCRPC and determine the MTD/highest exposure dose and schedule for KTX-2001 as a single agent.Part B: Investigate the safety and tolerability of KTX-2001+darolutamide in participants with mCRPC.Determine the RP2D of KTX-2001 based on data from Part A and Part B.
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase I
- Enrollment Status: Open
-
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase 3
- Enrollment Status: Open
-
This is a first-in-human Phase 1/2, multinational, multicenter, open-label study of HB-302/HB-301 alternating 2-vector therapy in participants with metastatic castration-resistant prostate cancer (mCRPC) comprising 2 phases: a Phase 1 Dose Escalation and recommended Phase 2 dose (RP2D) Confirmation, and a Phase 2 Dose Expansion.
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase I/II
- Enrollment Status: Closed
-
this study is being done in subjects with advanced neuroendocrine cancer (NEC) to:• Test different doses of the study drug, BI 764532, when given with the standard chemotherapy drugs, carboplatin and etoposide, to see which doses of BI 764532 have less unacceptable side effects. • Find the recommended dose of the study drug, BI 764532, when given with the standard chemotherapy drugs, that can be used in Part B of this study.• Test the study drug for safety and side effects.
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
To evaluate the safety and tolerability, and to establish a RP2D, of treatment combinations that have not been evaluated in a separate study. To evaluate the safety and tolerability for each treatment arm. To estimate the ORR per PCWG Modified RECIST 1.1, as assessedby BICR, for each treatment arm.
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase I/II
- Enrollment Status: Open
-
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912.
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase I
- Enrollment Status: Closed
-
A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant)and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase II
- Enrollment Status: Closed
-
To evaluate the safety and tolerability of SYNC-T SV-102 Therapy (Part 1 and Part 2). Incidence of AEs, SAEs, adverse events (AEs), treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), immune-related adverse reactions (imARs). To identify the maximum tolerated dose (MTD) and/or selected doses for optimization (Part 1 only)
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase II
- Enrollment Status: Open
-
To compare MK-5684 to alternative abiraterone acetate orenzalutamide with respect to overall survival in participants with mCRPC.
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase III
- Enrollment Status: Open
-
The purpose of this research study is to test the safety of study drug STAR0602, to see how well different doses of the study drug STAR0602 are tolerated in different groups of patients, to understand how the body absorbs and processes different doses of the study drug STAR0602. The is known as pharmacokinetics (PK), to understand the effect of the study drug on cells of the body and which patients might respond to study drug STAR0602. This is known as pharmacodynamics (PD), and assess the preliminary anti-tumor activity of the study drug as the only therapy used in subjects with advanced solid tumors.
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase I
- Enrollment Status: Open
-
The purpose of this study is to determine if the investigational drug, CLSP-1025, is safe, tolerable and can control or shrink tumors when given to HLA-A*02:01 positive people with advanced solid tumors with a p53 R175H mutation.
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase I
- Enrollment Status: Open
-
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
To determine whether adding abemaciclib to abiraterone plus prednisonea improves radiographic progression-free survival (rPFS).
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase III
- Enrollment Status: Closed
-
The main objective of the study is to measure the efficacy and safety of BT8009 as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC).
- Principal Investigator: Marijo Bilusic
- Study Phase: Phase II/III
- Enrollment Status: Not Accepting
